Improvement of Antialveolar echinococcosis efficacy of novel Albendazole-Bile acids Derivatives with Enhanced Oral Bioavailability.
Alveolar echinococcosis (AE) is a chronic and fatal infectious parasitic disease, which has not been well-researched. Current recommended therapies for AE by the World Health Organization include complete removal of the infected tissue followed by two years of albendazole (ABZ), administered orally,...
Main Authors: | Chunhui Hu, Meng Qin, Fabin Zhang, Ruixue Gao, Xuehui Gan, Tao Du |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | https://doi.org/10.1371/journal.pntd.0011031 |
Similar Items
-
Impact on Bile Acid Concentrations by Alveolar Echinococcosis and Treatment with Albendazole in Mice
by: Cristina Gómez, et al.
Published: (2021-07-01) -
Treatment of echinococcosis: albendazole and mebendazole – what else?
by: Hemphill Andrew, et al.
Published: (2014-01-01) -
Genotoxic effects of albendazole in patients medicated for cystic echinococcosis
by: Nuray Altintas, et al.
Published: (2007-06-01) -
Improving bioavailability and anthelmintic activity of albendazole by preparing albendazole-cyclodextrin complexes
by: García-Rodriguez J.J., et al.
Published: (2001-06-01) -
Severe adverse reaction induced by albendazole and praziquantel for cystic echinococcosis
by: Li Zhao, et al.
Published: (2023-01-01)